Last updated: 2026-10-13 12:29:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Eloxx Pharmaceuticals, Inc. (ELOX) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $14.59, with a market capitalisation of $47.21M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $14.59 to $23.40. This page covers its latest market performance, valuation, price trends and company information.
$47.21M | |
$14.91 | |
$10,824.00 | |
$14.59 | |
$13.89 | |
1.00 | |
45.03K | |
-- | |
$23.40 | |
$14.59 | |
-- | |
-- |
Eloxx Pharmaceuticals, Inc. (ELOX) is trading at $14.59 in pre-market trading as of 2026-10-13 11:48:00, up 5.04% ($0.70) from the previous close of $13.89
Pre-market trading shows how investors are pricing ELOX before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Eloxx Pharmaceuticals, Inc. (ELOX) moved from $15.51 to $14.59, representing a decline of 5.93% ($0.92).
The stock traded between $13.21 and $16.81 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 26.81 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0.0%
ELOX is currently trading at $14.59, placing it 0.0% of the way from its 52-week low of $14.59 to its 52-week high of $23.40. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 7 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Eloxx Pharmaceuticals, Inc. (ELOX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.